Status:
COMPLETED
Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Lead Sponsor:
AstraZeneca
Conditions:
Diabetes
Eligibility:
All Genders
18-77 years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to understand if saxagliptin is more effective than placebo as a treatment for type 2 diabetic subjects who are not controlled with diet and exercise
Detailed Description
All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to ...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Inadequate blood sugar control
Exclusion
- Previous treatment for diabetes
- Current treatment with other medications to lower blood sugar
- Major heart, liver or kidney problems
- Women who are pregnant or breastfeeding
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
365 Patients enrolled
Trial Details
Trial ID
NCT00316082
Start Date
June 1 2006
End Date
November 1 2008
Last Update
April 29 2015
Active Locations (74)
Enter a location and click search to find clinical trials sorted by distance.
1
Tomac, Inc.
Columbiana, Alabama, United States, 35051
2
Winston Technology, Inc.
Haleyville, Alabama, United States, 35565
3
Clinical Reseacrh Advantage/ Brown Family Medicine
Mesa, Arizona, United States, 85213
4
Strategos Medical Group
Bakersfield, California, United States, 93311